KR20100102163A - Ｃ형 간염 바이러스 항체 - Google Patents

Ｃ형 간염 바이러스 항체 Download PDF

Info

Publication number
KR20100102163A
KR20100102163A KR1020107015856A KR20107015856A KR20100102163A KR 20100102163 A KR20100102163 A KR 20100102163A KR 1020107015856 A KR1020107015856 A KR 1020107015856A KR 20107015856 A KR20107015856 A KR 20107015856A KR 20100102163 A KR20100102163 A KR 20100102163A
Authority
KR
South Korea
Prior art keywords
antibody
seq
antibodies
hcv
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107015856A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 제이. 매튜스
데이비드 지. 윌리암스
아르빈드 파텔
Original Assignee
메디칼 리서치 카운실 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디칼 리서치 카운실 테크놀로지 filed Critical 메디칼 리서치 카운실 테크놀로지
Publication of KR20100102163A publication Critical patent/KR20100102163A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
KR1020107015856A 2007-12-17 2008-12-17 Ｃ형 간염 바이러스 항체 Ceased KR20100102163A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17
US61/006,066 2007-12-17

Publications (1)

Publication Number Publication Date
KR20100102163A true KR20100102163A (ko) 2010-09-20

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015856A Ceased KR20100102163A (ko) 2007-12-17 2008-12-17 Ｃ형 간염 바이러스 항체

Country Status (18)

Country Link
US (1) US9193781B2 (enExample)
EP (1) EP2231704B1 (enExample)
JP (1) JP5763344B2 (enExample)
KR (1) KR20100102163A (enExample)
CN (1) CN101939334B (enExample)
AR (1) AR072039A1 (enExample)
AU (1) AU2008341542B2 (enExample)
BR (1) BRPI0821252A2 (enExample)
CA (1) CA2708740C (enExample)
CL (1) CL2008003784A1 (enExample)
IL (1) IL205795A0 (enExample)
MX (1) MX2010006767A (enExample)
NZ (1) NZ585622A (enExample)
PE (1) PE20091109A1 (enExample)
RU (1) RU2462475C2 (enExample)
TW (1) TW200940090A (enExample)
WO (1) WO2009081285A2 (enExample)
ZA (1) ZA201003509B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
EP1768490B1 (en) 2004-10-07 2010-06-09 Transmedics, Inc. Systems and methods for ex-vivo organ care
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9814230B2 (en) 2008-01-31 2017-11-14 Transmedics, Inc. Systems and methods for ex vivo lung care
KR20110101212A (ko) * 2008-12-17 2011-09-15 제넨테크, 인크. Ｃ형 간염 바이러스 조합 요법
AU2012242578B2 (en) 2011-04-14 2016-07-21 Transmedics, Inc. Organ care solution for ex-vivo machine perfusion of donor lungs
JP6158171B2 (ja) 2011-05-02 2017-07-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成ｃ型肝炎ゲノム、並びに、その製造方法及びその使用
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
KR20140106668A (ko) * 2011-12-09 2014-09-03 어플라이드 머티어리얼스, 인코포레이티드 가열 튜브를 냉각시키기 위한 열 교환기 및 그 냉각 방법
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
SG11201601423SA (en) 2013-09-19 2016-04-28 Novavax Inc Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
DK3151663T3 (da) 2014-06-02 2020-11-30 Transmedics Inc Ex vivo-organplejesystem
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
EP3229588B1 (en) 2014-12-12 2025-04-23 TransMedics, Inc. Apparatus and method for organ perfusion
CA2997267A1 (en) 2015-09-09 2017-03-16 Transmedics, Inc. Aortic cannula for ex vivo organ care system
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
CN109641955B (zh) * 2016-03-22 2022-07-08 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
ES2968062T3 (es) 2016-05-30 2024-05-07 Transmedics Inc Aparato y método de ventilación pulmonar ex vivo con presión exterior variable
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2272443B (en) * 1991-06-10 1995-10-25 Lucky Ltd Nucleotide and amino acid sequences of Korean hepatitis C virus
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
CA2429946A1 (en) * 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections

Also Published As

Publication number Publication date
CA2708740A1 (en) 2009-07-02
JP5763344B2 (ja) 2015-08-12
TW200940090A (en) 2009-10-01
EP2231704A2 (en) 2010-09-29
WO2009081285A2 (en) 2009-07-02
PE20091109A1 (es) 2009-08-12
RU2010129429A (ru) 2012-01-27
ZA201003509B (en) 2011-12-28
US20110002926A1 (en) 2011-01-06
CN101939334A (zh) 2011-01-05
CL2008003784A1 (es) 2009-08-14
MX2010006767A (es) 2010-10-05
WO2009081285A3 (en) 2010-08-26
CA2708740C (en) 2017-07-18
AU2008341542A1 (en) 2009-07-02
AU2008341542B2 (en) 2014-12-04
NZ585622A (en) 2012-10-26
AR072039A1 (es) 2010-08-04
CN101939334B (zh) 2015-01-14
IL205795A0 (en) 2010-11-30
EP2231704B1 (en) 2015-08-12
HK1144440A1 (en) 2011-02-18
BRPI0821252A2 (pt) 2015-06-16
US9193781B2 (en) 2015-11-24
RU2462475C2 (ru) 2012-09-27
JP2011505867A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
CN101939334B (zh) C型肝炎病毒抗体
US11136408B2 (en) Anti-PD-1 antibodies, method for producing same and method for using same
CA2707773C (en) Binding molecules to the human ox40 receptor
JP6797111B2 (ja) イヌｐｄ−ｌ１と結合するｐｄ−ｌ１抗体
EP3511344A1 (en) Neutralizing antibodies and methods of use thereof
KR20210045999A (ko) 인간 Tim-3에 대한 모노클로날 항체
JP2015145397A (ja) 抗α２インテグリン抗体を使用する処置
AU2021372706A1 (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
WO2021063352A1 (zh) 一种抗pd-l1抗原结合蛋白及其应用
US20120027722A1 (en) Hepatitis c virus combination therapy
US20250136696A1 (en) Anti-b7-h7 antibody or antigen-binding fragment thereof, and preparation method therefor and use thereof
KR20230117178A (ko) T 세포 인게이저 치료제의 개발 및 적용
HK1144440B (en) Hepatitis c virus antibodies
WO2022199527A1 (zh) 靶向肺炎链球菌溶血素的抗原结合蛋白及其用途
TW202417509A (zh) Slit2相關組合物和方法
CN120225558A (zh) 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体
HK1184168A1 (zh) 拮抗性抗il-7受体抗体及方法
OA19651A (en) Anti-Pd-1 antibodies, method for producing same and method for using same.
HK1227320A1 (en) Anti-efna4 antibody-drug conjugates

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160111

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160331

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160111

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I